GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Acadia Pharmaceuticals Inc. (ACAD) [hlAlert]

Rating:
Buy ACAD
up 2,299.36 %

Acadia Pharmaceuticals Inc. (ACAD) rated Buy with price target $24 by Ladenburg Thalmann

Posted on: Wednesday,  Aug 7, 2013  10:25 AM ET by Ladenburg Thalmann

Ladenburg Thalmann rated Buy Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) on 08/07/2013. Previously Ladenburg Thalmann rated Buy Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) on
04/30/2012., when the stock price was $1.58. Since then, Acadia Pharmaceuticals Inc. has gained 2299.37% as of 01/25/2016's recent price of $37.91.
If you would have followed the previous Ladenburg Thalmann's recommendation on ACAD, you would have gained 2299.36% of your investment in 1365 days.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company is developing a portfolio consisting of its four product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson?s disease psychosis. In addition, the Company has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, Inc., and ACP-106 in IND-track development. The Company?s product candidates include Pimavanserin, AGN-XX/YY, AC-262271 and ACP-106. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark.

Our Research Department takes a fresh, critical approach to analyzing primary sources and developing proprietary research. Many individuals, institutions, portfolio managers and hedge fund managers, on all levels, have been neglected by brokerage firms ignoring the demands for unbiased research. Ladenburg Thalmann provides a superior branded in-depth research product geared only to action-oriented investment ideas. Ladenburg Thalmann’s proprietary equity research tries to uncover crucial information before the rest of the Street. Our analysts concentrate on uncovered and under-covered stocks and have a small to mid-cap focus. We will not shy away from large cap names as long as we can bring value to our clients through timely, differentiated ideas.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/7/2013 10:25 AM Buy
None
19.68 24.00
as of 12/13/2013
1 Week down  -5.57 %
1 Month up  0.21 %
3 Months down  -0.38 %
1 YTD up  395.26 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/11/2013 10:25 AM Buy
None
11.73 15.00
3/13/2013 8:25 AM Buy
None
6.18 9.00
11/27/2012 1:25 PM Buy
None
5.58 8.00
4/30/2012 8:25 AM Buy
None
1.58

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy